ライフサイエンスコーパス: isocitrate dehydrogenase

1 ive carboxylation flux through mitochondrial isocitrate dehydrogenase.

2 mes, notably the mitochondrial NAD-dependent isocitrate dehydrogenase.

3 inated hydroxyl group of isocitrate bound to isocitrate dehydrogenase.

4 catalytic activity of porcine NADP-dependent isocitrate dehydrogenase.

5 d crystal structure of porcine NADP-specific isocitrate dehydrogenase.

6 the tetragonal and the orthorhombic forms of isocitrate dehydrogenase.

7 n, and purified to yield homogeneous porcine isocitrate dehydrogenase.

8 most extensively studied among the mammalian isocitrate dehydrogenases.

9 Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequ

10 tive carboxylation of alpha-ketoglutarate by isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) was recen

11 We found recurrent isocitrate dehydrogenase 1 (IDH1) and IDH2 (28%) gene mu

12 Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the

13 1 was exclusive to tumors carrying wild-type isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and was

14 Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been ide

15 sue of Blood, Shi et al describe the role of isocitrate dehydrogenase 1 (idh1) and idh2 in developmen

16 Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in cancer st

17 Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydro

18 Monoallelic point mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) and its mitochondrial

19 Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature o

20 Mutations of isocitrate dehydrogenase 1 (IDH1) are frequently found i

21 Mutations at the arginine residue (R132) in isocitrate dehydrogenase 1 (IDH1) are frequently identif

22 Gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) are key drivers of hem

23 Here, we characterize isocitrate dehydrogenase 1 (IDH1) as a transcriptional t

24 in HuR-deficient PDAC cell lines identified isocitrate dehydrogenase 1 (IDH1) as the sole antioxidan

25 Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)

26 Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently

27 Mutant isocitrate dehydrogenase 1 (IDH1) catalyzes the producti

28 Isocitrate dehydrogenase 1 (IDH1) catalyzes the reversib

29 vosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for t

30 grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggr

31 Mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

32 Gain-of-function mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

33 The recent identification of isocitrate dehydrogenase 1 (IDH1) gene mutations in glio

34 Hotspot mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in a number

35 Mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in most LGG

36 Two mutant forms (R132H and R132C) of isocitrate dehydrogenase 1 (IDH1) have been associated w

37 nd recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients

38 Isocitrate dehydrogenase 1 (IDH1) is mutated in various

39 Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as t

40 anscripts were found in GBMs irrespective of isocitrate dehydrogenase 1 (IDH1) mutation status.

41 se dependent, acted synergistically with the isocitrate dehydrogenase 1 (IDH1) mutation, and resemble

42 Absence of isocitrate dehydrogenase 1 (IDH1) mutation, asymptomatic

43 Isocitrate dehydrogenase 1 (IDH1) mutations occur in app

44 Isocitrate dehydrogenase 1 (IDH1) mutations occur in mos

45 Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gl

46 letion) and mutations in the metabolic genes isocitrate dehydrogenase 1 (IDH1) or IDH2(1,2), were sha

47 exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2.

48 dromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of whi

49 Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial h

50 The human, cytosolic enzyme isocitrate dehydrogenase 1 (IDH1) reversibly converts is

51 we performed genome-wide target profiling of isocitrate dehydrogenase 1 (IDH1), a novel RBP.

52 Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by

53 Mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), frequently found in g

54 One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in m

55 se reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1).

56 that can modulate the activity of the enzyme isocitrate dehydrogenase 1 (IDH1).

57 ydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme.

58 oblastomas are characterized by mutations in isocitrate dehydrogenase 1 (IDHmut).

59 Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key

60 Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer

61 zygously expressed single-point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2, respect

62 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been disc

63 Mutations in the genes encoding isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in a var

64 Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in sever

65 aking is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are

66 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present i

67 Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the development

68 d ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2, respectively.

69 ers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-kappaB pathway, an

70 IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of

71 Isocitrate dehydrogenase 1 mutations drive human gliomag

72 rganization 2007 tumor grade, histology, and isocitrate dehydrogenase 1 R132H mutational status.

73 ssigned NF1-glioma to LGm6, a poorly defined Isocitrate Dehydrogenase 1 wild-type subgroup enriched w

74 ade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor sam

75 orme that identified IDH1, the gene encoding isocitrate dehydrogenase 1, as target for cancer-driving

76 With DESI MS, we identify isocitrate dehydrogenase 1-mutant tumors with both high

77 D-2-hydroxyglutarate imaging is possible in isocitrate dehydrogenase 1-mutated human glioma by using

78 Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in u

79 e (R-2HG), produced at high levels by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was repor

80 Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG islan

81 d hematopoietic differentiation in AML after isocitrate dehydrogenase 1/2 mutation and 2-hydroxygluta

82 levels in cancer cells with gain-of-function isocitrate dehydrogenase 1/2 mutations.

83 g genetic anchor to drive patient selection (isocitrate dehydrogenase 1/2, Enolase 2).

84 Mutations in isocitrate dehydrogenases 1 and 2 (IDH(mut)) are present

85 Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have b

86 Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur

87 omatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).

88 n the tricarboxylic acid (TCA) cycle enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights th

89 tions in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several

90 Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that produce

91 Isocitrate dehydrogenase-1 (IDH1) is mutated in up to 25

92 ptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants.

93 Recently, it was shown that somatic isocitrate dehydrogenase-1 (IDH1) mutations, frequently

94 metabolism was highly dependent on cytosolic isocitrate dehydrogenase-1 (IDH1), because the activity

95 This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is a

96 Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common driver

97 lignancies owing to somatic mutations in the isocitrate dehydrogenase-1 or -2 (IDH1 or IDH2) genes, o

98 hmdC levels were independent of mutations in isocitrate dehydrogenase-1.

99 The development of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mu

100 pecies (ROS) by deacetylating and activating isocitrate dehydrogenase 2 (IDH2) and superoxide dismuta

101 We show that downregulation of isocitrate dehydrogenase 2 (IDH2) and TET family enzymes

102 Mitochondrial isocitrate dehydrogenase 2 (IDH2) converts NADP(+) to NA

103 The mitochondrial matrix protein isocitrate dehydrogenase 2 (IDH2) is a major source of N

104 cute myeloid leukemia (AML) treated with the isocitrate dehydrogenase 2 (IDH2) mutant-specific inhibi

105 ochondrial superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) observed in untreated

106 Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in approximately

107 Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers,

108 ons in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2

109 Isocitrate dehydrogenase 2 (IDH2) was identified as a to

110 and colleagues demonstrate the mutations in isocitrate dehydrogenase 2 (IDH2), commonly found in acu

111 tly deacetylates and activates mitochondrial isocitrate dehydrogenase 2 (Idh2), leading to increased

112 antioxidant system through the regulation of isocitrate dehydrogenase 2 (Idh2).

113 of unfavorable outcome, such as mutations in isocitrate dehydrogenase 2 (IDH2-R172) and overexpressio

114 rate-limiting tricarboxylic acid cycle (TCA) isocitrate dehydrogenase 2 and superoxide dismutase 2, c

115 findings demonstrate that MitEpac1 inhibits isocitrate dehydrogenase 2 via the mitochondrial recruit

116 which in turn decreased expression of IDH2 (isocitrate dehydrogenase 2).

117 ients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur

118 Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of

119 pment of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mutations has been described

120 ticipation of concurrent NADPH sources (i.e. isocitrate dehydrogenase-2, malic enzymes, and glutamate

121 f the pyruvate dehydrogenase complex (-41%), isocitrate dehydrogenase (-27%), and the alpha-ketogluta

122 nd that the aberrant expression of wild-type isocitrate dehydrogenase 3alpha (IDH3alpha), a subunit o

123 tion cryo-EM structures of the cancer target isocitrate dehydrogenase (93 kDa) and identify the natur

124 termediates reveals the reversibility of the isocitrate dehydrogenase + aconitase reactions, even in

125 rogenase, 2-oxoxglutarate dehydrogenase, and isocitrate dehydrogenase activities of the Krebs cycle i

126 The mutant was devoid of isocitrate dehydrogenase activity and of immunologically

127 hypoxia elicited both aconitase and NADP(+)-isocitrate dehydrogenase activity losses.

128 Hepatic isocitrate dehydrogenase activity was also decreased, wh

129 of Bradyrhizobium japonicum USDA110 lacking isocitrate dehydrogenase activity was created to determi

130 regulates activity of the TCA cycle enzymes isocitrate dehydrogenase and alpha-ketoglutarate dehydro

131 inase, pyruvate kinase, phosphofructokinase, isocitrate dehydrogenase and citric synthase) tend to be

132 ssion changes of some metabolic genes (e.g., isocitrate dehydrogenase and fumarate hydratase) may enh

133 so investigated inhibitors of NADP-dependent isocitrate dehydrogenase and mitochondrial citrate expor

134 The crystal structure of Escherichia coli isocitrate dehydrogenase and sequence alignment of porci

135 ylic acid cycle (oxoglutarate dehydrogenase, isocitrate dehydrogenase) and glycine decarboxylase.

136 e gene encoding the NADP(+)-dependent enzyme isocitrate dehydrogenase, and cadherin 18, type 2 (CDH14

137 ytosolic isoforms of NADP(+)/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of g

138 mes: malate dehydrogenase, citrate synthase, isocitrate dehydrogenase, and succinyl-CoA synthetase.

139 lternative CAM cycle involving mitochondrial isocitrate dehydrogenase as a potential contributor to i

140 hydrogenase alpha levels and lower levels of isocitrate dehydrogenase, both proteins involved in the

141 was consistent with allosteric inhibition of isocitrate dehydrogenase by P-enolpyruvate.

142 al water-saving effect of carbon fixation by isocitrate dehydrogenase can reach 11% total water savin

143 ccinate dehydrogenase, fumarate hydratase or isocitrate dehydrogenase, can dysregulate specific 2OGDD

144 ase and to stimulate the reverse reaction of isocitrate dehydrogenase (carboxylation of alpha-KG to i

145 Isocitrate dehydrogenase catalyses the two step, acid ba

146 The downstream isocitrate dehydrogenase (citC) gene appears to be part

147 ydrogenase was used to express the enzyme in isocitrate dehydrogenase-deficient E. coli.

148 insulin secretion is amplified by cytosolic isocitrate dehydrogenase-dependent transfer of reducing

149 hia coli, the homodimeric Krebs cycle enzyme isocitrate dehydrogenase (EcIDH) is regulated by reversi

150 Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur

151 e production of 2-hydroxyglutarate by mutant isocitrate dehydrogenase enzymes, we can observe metabol

152 Mechanistically, isocitrate dehydrogenase expression and the production o

153 Isocitrate dehydrogenase from Bacillus subtilis (BsIDH)

154 d on the crystal structure of NADP-dependent isocitrate dehydrogenases from Escherichia coli, Bacillu

155 we showed that citrate synthase, aconitase, isocitrate dehydrogenase, fumarase, malate dehydrogenase

156 Mutations in the isocitrate dehydrogenase gene (IDH1) were recently descr

157 with glioma harbor specific mutations in the isocitrate dehydrogenase gene IDH1 that associate with a

158 f the structure of the porcine NADP-specific isocitrate dehydrogenase generated by the Insight II Mod

159 Mutations in the isocitrate dehydrogenase genes (IDH1/2) occur often in d

160 glioma-associated mutations into the NADP(+ )isocitrate dehydrogenase genes (IDP1, IDP2, IDP3) in Sac

161 Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among t

162 occurring mutations in the NADP(+)-dependent isocitrate dehydrogenase genes IDH1 and IDH2 These mutat

163 e chromatin architecture at the promoters of isocitrate dehydrogenase genes to promote transcription

164 Two putative Methanococcus jannaschii isocitrate dehydrogenase genes, MJ1596 and MJ0720, were

165 ies of homologous isozymes of NADP+-specific isocitrate dehydrogenase, histidine-tagged forms of yeas

166 rs based on the DNA base sequence within the isocitrate dehydrogenase (icd) gene to amplify a 1,200-b

167 tigated the role of cytosolic NADP-dependent isocitrate dehydrogenase (ICDc) in control of GSIS in be

168 of isocitrate and engagement with cytosolic isocitrate dehydrogenase (ICDc) may be one key pathway,

169 ate carrier and the cytosolic NADP-dependent isocitrate dehydrogenase (ICDc), is involved in control

170 (via isocitrate lyase) or the TCA cycle (via isocitrate dehydrogenase (ICDH) activity) and we sought

171 her hand, between isocitrate lyase (ICL) and isocitrate dehydrogenase (ICDH) for their common substra

172 Isocitrate dehydrogenase (ICDH) is either an integral pa

173 harboring a mutation in the gene coding for isocitrate dehydrogenase ( IDH).

174 Mutant isocitrate dehydrogenase (IDH) 1 and 2 proteins alter th

175 1 and aminopeptidase), inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody-base

176 associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arg

177 Cit2 and reduced expression of NAD-specific isocitrate dehydrogenase (Idh) and aconitase (Aco1) in p

178 Triglyceride concentration and isocitrate dehydrogenase (IDH) and glucose-6-phosphate d

179 Mutations in isocitrate dehydrogenase (IDH) are the most prevalent ge

180 dinucleotide phosphate (NADP) by prokaryotic isocitrate dehydrogenase (IDH) arose around the time euk

181 Isocitrate dehydrogenase (IDH) catalyzes the oxidative d

182 porcine heart mitochondrial NADP+-dependent isocitrate dehydrogenase (IDH) complexed with Mn2+ and i

183 Aconitase and isocitrate dehydrogenase (IDH) enzyme activities were de

184 The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-

185 by the discovery of mutations involving the isocitrate dehydrogenase (IDH) enzymes.

186 ties between isocitrate and isopropylmalate, isocitrate dehydrogenase (IDH) exhibits a strong prefere

187 activity for grading and characterization of isocitrate dehydrogenase (IDH) gene mutation status of g

188 ne promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined.

189 Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequen

190 Somatic mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur

191 expression of ATP-citrate synthase (ACS) and isocitrate dehydrogenase (IDH) genes in cold-treated tom

192 talline porcine mitochondrial NADP-dependent isocitrate dehydrogenase (IDH) has been determined in co

193 NAD+-specific isocitrate dehydrogenase (IDH) has been reported to bind

194 Yeast mitochondrial NAD+-specific isocitrate dehydrogenase (IDH) has previously been shown

195 discovery of mutations in the genes encoding isocitrate dehydrogenase (IDH) has uncovered a critical

196 terozygous mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) in subsets of cancers, in

197 The human NAD-dependent isocitrate dehydrogenase (IDH) is a heterotetrameric mit

198 Isocitrate dehydrogenase (IDH) is a reversible enzyme th

199 Human NAD-dependent isocitrate dehydrogenase (IDH) is allosterically activat

200 Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an allosterically regu

201 Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an allosterically regu

202 Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an octamer containing

203 osteric regulatory properties, NAD+-specific isocitrate dehydrogenase (IDH) is believed to control fl

204 Among a number of novel genes, isocitrate dehydrogenase (IDH) is recurrently mutated in

205 Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 an

206 stigation of metabolic pathways disturbed in isocitrate dehydrogenase (IDH) mutant tumors revealed th

207 er, accuracy was poorer when tumors harbored isocitrate dehydrogenase (IDH) mutations (91% in IDH-wil

208 Background Isocitrate dehydrogenase (IDH) mutations are highly freq

209 s caused by recurrent mutations, such as the isocitrate dehydrogenase (IDH) mutations found in 15% of

210 Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the met

211 ation in a subset of glioblastomas harboring isocitrate dehydrogenase (IDH) mutations, but metabolic

212 associated with MYC signaling, but not with isocitrate dehydrogenase (IDH) mutations, suggesting a d

213 The tricarboxylic acid cycle NAD+-specific isocitrate dehydrogenase (IDH) of Saccharomyces cerevisi

214 mine the effects of large-scale variation in isocitrate dehydrogenase (IDH) or glucose-6-phosphate de

215 that shows how robust behavior arises in the isocitrate dehydrogenase (IDH) regulatory system of Esch

216 ally available MRI parameters for predicting isocitrate dehydrogenase (IDH) status in patients with g

217 Isocitrate dehydrogenase (IDH)(1) of Escherichia coli is

218 NAD+-dependent isocitrate dehydrogenase (IDH), a key regulatory enzyme

219 drogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH), advancing and challengin

220 IDP2, and/or the mitochondrial NAD+-specific isocitrate dehydrogenase (IDH), metabolite measurements

221 The human NAD-dependent isocitrate dehydrogenase (IDH), with three types of subu

222 role is to consume acetyl-CoA, which unlocks isocitrate dehydrogenase (IDH)-dependent reductive carbo

223 We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combini

224 determine whether MRI/CT analysis identifies isocitrate dehydrogenase (IDH)-mutant gliomas misassigne

225 ta-N-acetylglucosamine transferase (OGT) and isocitrate dehydrogenase (IDH).

226 ide adenine dinucleotide phosphate-dependent isocitrate dehydrogenase (IDH)1 and IDH2 frequently aris

227 Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at th

228 y, we explored the function of mitochondrial isocitrate dehydrogenase (IDH)2, a tricarboxylic acid cy

229 atio and inhibits expression and activity of isocitrate dehydrogenase (IDH); and, via 13C-labeling st

230 imaging-defined invasive phenotypes of both isocitrate dehydrogenase (IDH-1)-mutated and IDH-1 wild-

231 Isocitrate dehydrogenases (IDH) convert isocitrate to al

232 scribed metabolic oncogenic factors: mutated isocitrate dehydrogenases (IDH), succinate dehydrogenase

233 glutarate (catalyzed by reverse flux through isocitrate dehydrogenase, IDH).

234 Here, we report that the isocitrate dehydrogenase IDH1 is the most strongly upreg

235 .35 million compounds against mutant (R132H) isocitrate dehydrogenase IDH1 led to the identification

236 CMA degrades isocitrate dehydrogenases IDH1 and IDH2 and reduces leve

237 lic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently

238 Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recen

239 utarate (2HG), generated by mutated forms of isocitrate dehydrogenase (IDH1 and IDH2), reduces the ex

240 Mutations in the cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDH1) occur in several types o

241 drug strategies and single-gene mutations in isocitrate dehydrogenases (IDH1/2).

242 Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate

243 Ps harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displaye

244 rboxylated by the NADPH-linked mitochondrial isocitrate dehydrogenase (IDH2) to form isocitrate, whic

245 or a non-allosteric bacterial NAD+-specific isocitrate dehydrogenase (IDHa).

246 Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high le

247 Mitochondrial NAD(+)-specific isocitrate dehydrogenases (IDHs) are key regulators of f

248 in arginine N-methyltransferases (PRMTs) and isocitrate dehydrogenases (IDHs), and highlight the most

249 mRNAs by yeast mitochondrial NADP+-specific isocitrate dehydrogenase (IDP1) but not by the correspon

250 he gene encoding cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDP2).

251 ic source of NADPH, cytosolic NADP+-specific isocitrate dehydrogenase (Idp2p).

252 d outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetical

253 and the expression and activity of TETs and isocitrate dehydrogenases in primary human chondrocytes.

254 e FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs

255 search terms were used: IDH, IDH1, IDH2, and isocitrate dehydrogenase, in conjunction with glioma or

256 he basic structural/functional unit of yeast isocitrate dehydrogenase is a heterodimer of IDH1 and ID

257 Mammalian NAD-dependent isocitrate dehydrogenase is an allosteric enzyme, activa

258 Yeast NAD(+)-specific isocitrate dehydrogenase is an allosterically regulated

259 Yeast NAD(+)-specific isocitrate dehydrogenase is an allosterically regulated

260 Yeast mitochondrial NAD(+)-specific isocitrate dehydrogenase is an octamer composed of four

261 ts that His(309) of pig heart NADP-dependent isocitrate dehydrogenase is equivalent to His(339) of th

262 Isocitrate dehydrogenase is mutated at a key active site

263 22% of the ATP needed for biosynthesis; (ii) isocitrate dehydrogenase is reversible in vivo; (iii) ab

264 Pig heart mitochondrial NADP-dependent isocitrate dehydrogenase is the most extensively studied

265 acid substrate, comprising one subfamily and isocitrate dehydrogenase, isopropylmalate dehydrogenase,

266 hosphorylation catalyzed by the bifunctional isocitrate dehydrogenase kinase/phosphatase (IDHKP), and

267 Previous studies have shown that mutant isocitrate-dehydrogenase (mIDH)1/2 glioma cells convert

268 The isocitrate dehydrogenase mutant, strain 5051, was constr

269 ts: expression was elevated in aconitase and isocitrate dehydrogenase mutants, diminished in alpha-ke

270 The mass spectra also indicate the isocitrate dehydrogenase mutation status of the tumor vi

271 anine-DNA methyltransferase-methylation, and isocitrate dehydrogenase mutation status, the proportion

272 prognostic and therapeutic consequences: (a) isocitrate dehydrogenase mutation; (b) the combined loss

273 features or genetic alterations, except for isocitrate dehydrogenase mutations (IDH(mut)) that were

274 t developments and implications in regard to isocitrate dehydrogenase mutations in chondrosarcoma, a

275 at might be relevant in cancer cells bearing isocitrate dehydrogenase mutations.

276 Isocitrate-dehydrogenase mutations (OR = 2.52, p = 0.026

277 B, encoding the beta-subunit of NAD-specific isocitrate dehydrogenase (NAD-IDH, or IDH3), which is be

278 We measured tissue levels of NADP-linked isocitrate dehydrogenase (NADP-ICDH), glucose-6-phosphat

279 NADP-specific isocitrate dehydrogenase (NADP-IDH, or IDH2), an enzyme

280 mRNAs and enzyme activities of the cytosolic isocitrate dehydrogenase or glucose-6-phosphate dehydrog

281 -(13)C]oxaloacetate to generate (13)CO(2) at isocitrate dehydrogenase, or decarboxylation of [1-(13)C

282 Pig heart NADP-dependent isocitrate dehydrogenase requires a divalent metal catio

283 Pig heart mitochondrial NADP-dependent isocitrate dehydrogenase requires a divalent metal ion f

284 ein, and in the phosphorylation cycle of the isocitrate dehydrogenase, respectively.

285 tumor morphologic characteristics predicted isocitrate dehydrogenase status in World Health Organiza

286 Isocitrate dehydrogenase subunits Idh1p and Idh2p were a

287 ystallographic structure of Escherichia coli isocitrate dehydrogenase suggest that both yeast subunit

288 d sequence alignment of porcine with E. coli isocitrate dehydrogenase suggests that the porcine Arg(1

289 mily as HIcDH, including isopropylmalate and isocitrate dehydrogenases, suggests all of the family me

290 glutarate in cells results from mutations to isocitrate dehydrogenase that correlate with cancer.

291 s maintained largely by transhydrogenase and isocitrate dehydrogenase, the mechanisms responsible for

292 sis of the crystal structure of E. coli NADP-isocitrate dehydrogenase, the residues Asp(253), Asp(273

293 oenolpyruvate carboxylase and NADP-dependent isocitrate dehydrogenase transcripts in the transgenic f

294 hat specifically binds an epitope of mutated isocitrate dehydrogenase type 1 (IDH1R132H), which is fr

295 of Insight II, a structure for porcine NADP-isocitrate dehydrogenase was built based on the X-ray co

296 alpha, beta, and gamma subunits of the human isocitrate dehydrogenase was used to express the enzyme

297 rg99, and gamma-Arg97 of human NAD-dependent isocitrate dehydrogenase were chosen as candidates for m

298 rom alpha-ketoglutarate (alpha-KG) by mutant isocitrate dehydrogenase, whereas l-(S)-2-HG is generate

299 tly map to genes for aconitate hydratase and isocitrate dehydrogenase, which are expected to alter ce

300 c MRI were retrospectively selected (36 with isocitrate dehydrogenase wild-type [IDH(wt)], 16 with mu